| 5.265 -0.035 (-0.66%) | 04-25 15:36 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.7  |
1-year : | 8.8 |
| Resists | First : | 6.59 |
Second : | 7.53 |
| Pivot price | 5.79 |
|||
| Supports | First : | 5.07 |
Second : | 4.21 |
| MAs | MA(5) : | 5.38 |
MA(20) : | 6.01 |
| MA(100) : | 7.95 |
MA(250) : | 8.14 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 8.5 |
D(3) : | 9.7 |
| RSI | RSI(14): 31.3 |
|||
| 52-week | High : | 12 | Low : | 5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ WALD ] has closed above bottom band by 21.8%. Bollinger Bands are 10.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.43 - 5.47 | 5.47 - 5.5 |
| Low: | 5.07 - 5.11 | 5.11 - 5.14 |
| Close: | 5.25 - 5.31 | 5.31 - 5.35 |
Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.
Thu, 25 Apr 2024
Learn to Evaluate (WALD) using the Charts - Stock Traders Daily
Wed, 24 Apr 2024
Waldencast (NASDAQ:WALD) Shares Down 4.1% - MarketBeat
Mon, 22 Apr 2024
ROSEN, LEADING INVESTOR COUNSEL, Encourages Waldencast plc Investors to Inquire About Securities Class ... - The Globe and Mail
Mon, 22 Apr 2024
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Waldencast plc and ... - The Globe and Mail
Mon, 22 Apr 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD - The Globe and Mail
Mon, 22 Apr 2024
WALDENCAST ALERT: Bragar Eagel & Squire, P.C. is Investigating Waldencast plc on Behalf of Waldencast ... - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Technology
|
|
|
Industry:
Software - Application
|
|
| Shares Out | 101 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 56.6 (%) |
| Held by Institutions | 37.9 (%) |
| Shares Short | 697 (K) |
| Shares Short P.Month | 868 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.69 |
| Profit Margin | -55.2 % |
| Operating Margin | -32.3 % |
| Return on Assets (ttm) | -8.9 % |
| Return on Equity (ttm) | -51.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.72 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -29.31 |
| PEG Ratio | 0 |
| Price to Book value | 0.92 |
| Price to Sales | 1.93 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|